Humoral and cellular immune monitoring might be useful to identify liver transplant recipients at risk for development of infection
- PMID: 18657086
- DOI: 10.1111/j.1399-3062.2008.00329.x
Humoral and cellular immune monitoring might be useful to identify liver transplant recipients at risk for development of infection
Abstract
Orthotopic liver transplantation (OLT) is a successful therapy for patients with end-stage liver disease, and infection remains a significant cause of morbidity and mortality for patients undergoing this procedure. To assess humoral and cellular immunity markers as potential risk factors for development of infection, 46 consecutive liver transplant recipients (hepatitis C virus cirrhosis [n=17], alcoholic liver disease [n=15], hepatocellular carcinoma [n=9], autoimmune hepatitis [n=2], and other [n=3]) performed at a single center were prospectively studied. Maintenance therapy included tacrolimus (n=37) or cyclosporine (n=9) and prednisone. During follow-up, 27 patients had at least 1 episode of infection (58.7%). Pre-OLT immunoglobulin G (IgG) hypergammaglobulinemia (relative risk [RR] 2.78; 95% confidence interval [CI], 1.17-6.60, P=0.02), pre-OLT IgA hypergammaglobulinemia (RR 2.77, CI=1.24-6.19, P=0.012), and pre-OLT C3 hypocomplementemia (RR 3.02, CI=1.21-7.55, P=0.018) were associated with an increased risk for development of infection. Monitoring of Ig and complement levels might help to identify the risk of developing infection in OLT.
Similar articles
-
IgG monitoring to identify the risk for development of infection in heart transplant recipients.Transpl Infect Dis. 2006 Mar;8(1):49-53. doi: 10.1111/j.1399-3062.2006.00136.x. Transpl Infect Dis. 2006. PMID: 16623821
-
Decreased levels of serum immunoglobulins as a risk factor for infection after heart transplantation.Transplant Proc. 2005 Nov;37(9):4046-9. doi: 10.1016/j.transproceed.2005.09.153. Transplant Proc. 2005. PMID: 16386623
-
Alternate-day prednisone in the maintenance immunosuppressive therapy after orthotopic liver transplantation.Clin Transplant. 1995 Aug;9(4):322-5. Clin Transplant. 1995. PMID: 7579741
-
New-onset diabetes after liver transplantation: from pathogenesis to management.Liver Transpl. 2005 Jun;11(6):612-20. doi: 10.1002/lt.20439. Liver Transpl. 2005. PMID: 15915488 Review.
-
Coccidioidomycosis in liver transplantation.Liver Transpl. 2006 Jan;12(1):31-9. doi: 10.1002/lt.20654. Liver Transpl. 2006. PMID: 16382459 Review.
Cited by
-
Clinical immune-monitoring strategies for predicting infection risk in solid organ transplantation.Clin Transl Immunology. 2014 Feb 28;3(2):e12. doi: 10.1038/cti.2014.3. eCollection 2014 Feb. Clin Transl Immunology. 2014. PMID: 25505960 Free PMC article. Review.
-
The Contribution of Serum Complement Component 3 Levels to 90-Day Mortality in Living Donor Liver Transplantation.Front Immunol. 2021 Jul 19;12:652677. doi: 10.3389/fimmu.2021.652677. eCollection 2021. Front Immunol. 2021. PMID: 34349754 Free PMC article.
-
Immune monitoring post liver transplant.World J Transplant. 2014 Mar 24;4(1):30-9. doi: 10.5500/wjt.v4.i1.30. World J Transplant. 2014. PMID: 24669365 Free PMC article. Review.
-
Targeting FcRn for immunomodulation: Benefits, risks, and practical considerations.J Allergy Clin Immunol. 2020 Sep;146(3):479-491.e5. doi: 10.1016/j.jaci.2020.07.016. J Allergy Clin Immunol. 2020. PMID: 32896308 Free PMC article. Review.
-
The Expanding Field of Secondary Antibody Deficiency: Causes, Diagnosis, and Management.Front Immunol. 2019 Feb 8;10:33. doi: 10.3389/fimmu.2019.00033. eCollection 2019. Front Immunol. 2019. PMID: 30800120 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
